Revvity to Present at J.P. Morgan Healthcare Conference
Revvity, Inc. (NYSE: RVTY) was upgraded by analysts at Bank of America Co. from a "neutral" rating to a "buy" rating. They now have a $138.00 price target on the stock.
Revvity, Inc. (NYSE: RVTY) had its price target lowered by analysts at Barclays PLC from $140.00 to $135.00. They now have an "overweight" rating on the stock.
Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK
Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference